APLS stock forecast
Our latest prediction for Apellis Pharmaceuticals, Inc.'s stock price was made on the Sept. 15, 2020 when the stock price was at 31.20$.
In the short term (2weeks), APLS's stock price should underperform the market by -2.75%. During that period the price should oscillate between -10.59% and +8.66%.
In the medium term (3months), APLS's stock price should underperform the market by -6.79%. During that period the price should oscillate between -41.05% and +20.58%.Get email alerts
Create a solid portfolio with APLS
About Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which develops novel therapeutic compounds. It develops complement immunotherapies for the treatment of complement-dependent autoimmune and inflammatory diseases through APL-2 product. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -6.74$ per share.
The book value per share is 2.18$
Three months stock forecastSept. 15, 2020
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|